X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
canagliflozin (380) 380
humans (363) 363
index medicus (328) 328
diabetes mellitus, type 2 - drug therapy (305) 305
type 2 diabetes (214) 214
diabetes (208) 208
hypoglycemic agents - therapeutic use (207) 207
hypoglycemic agents - adverse effects (199) 199
male (197) 197
female (193) 193
glucose (176) 176
middle aged (169) 169
sodium-glucose transporter 2 - antagonists & inhibitors (163) 163
dapagliflozin (160) 160
endocrinology & metabolism (155) 155
double-blind (146) 146
safety (138) 138
aged (127) 127
glucosides - therapeutic use (123) 123
canagliflozin - therapeutic use (121) 121
type 2 diabetes mellitus (115) 115
canagliflozin - adverse effects (113) 113
glucosides - adverse effects (112) 112
empagliflozin (109) 109
adult (106) 106
efficacy (105) 105
metformin (105) 105
diabetes mellitus, type 2 - blood (103) 103
diabetes mellitus (99) 99
treatment outcome (99) 99
glycemic control (97) 97
medicine, general & internal (96) 96
hypoglycemic agents - administration & dosage (95) 95
pharmacology & pharmacy (91) 91
double-blind method (86) 86
insulin (86) 86
sglt2 inhibitor (86) 86
blood glucose - drug effects (85) 85
dextrose (85) 85
mellitus (82) 82
blood pressure (78) 78
thiophenes - therapeutic use (74) 74
blood glucose - metabolism (72) 72
sodium (72) 72
drug therapy (71) 71
care and treatment (70) 70
body weight (68) 68
thiophenes - adverse effects (67) 67
clinical trials (65) 65
monotherapy (64) 64
sglt2 inhibitors (63) 63
benzhydryl compounds - therapeutic use (62) 62
inadequate glycemic control (62) 62
hypoglycemic agents - pharmacology (57) 57
sitagliptin (57) 57
drug therapy, combination (55) 55
glucosides - administration & dosage (54) 54
glycated hemoglobin a - metabolism (54) 54
add-on (53) 53
analysis (53) 53
benzhydryl compounds - adverse effects (53) 53
dose-response relationship, drug (53) 53
hypoglycemic agents (51) 51
internal medicine (50) 50
sodium-glucose transporter 2 - metabolism (50) 50
blood pressure - drug effects (49) 49
diabetes therapy (49) 49
hypoglycemia (49) 49
hyperglycemia (48) 48
sglt2 (48) 48
canagliflozin - administration & dosage (47) 47
hemoglobin (46) 46
hypoglycemia - chemically induced (44) 44
risk factors (44) 44
diabetes mellitus, type 2 - complications (43) 43
glucosides - pharmacology (43) 43
patients (43) 43
abridged index medicus (42) 42
diabetes mellitus, type 2 - metabolism (42) 42
inhibitor (42) 42
randomized controlled trials as topic (42) 42
glucose cotransporter 2 (41) 41
medicine, research & experimental (40) 40
long-term efficacy (39) 39
placebo (39) 39
thiophenes - administration & dosage (39) 39
type-2 diabetes-mellitus (39) 39
body weight - drug effects (38) 38
research (37) 37
sulfonylurea (37) 37
diabetes mellitus, type 2 - physiopathology (36) 36
glycosylated hemoglobin (36) 36
mortality (36) 36
young adult (36) 36
cardiovascular disease (35) 35
complications and side effects (35) 35
metformin - therapeutic use (35) 35
studies (35) 35
body mass index (33) 33
endocrinology (33) 33
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CELL DEATH & DISEASE, ISSN 2041-4889, 02/2018, Volume 9, Issue 2, pp. 226 - 13
Recent FDA Drug Safety Communications report an increased risk for acute kidney injury in patients treated with the gliflozin class of sodium/glucose... 
BIOCHEMICAL ASSAYS | GLUCOSE COTRANSPORTER 2 | TCA CYCLE | AEROBIC GLYCOLYSIS | KIDNEY INJURY | CELL-PROLIFERATION | TYPE-2 DIABETES-MELLITUS | PROXIMAL TUBULE | CHRONIC SAFETY | ELECTRON-TRANSPORT | CELL BIOLOGY | Mitochondria - enzymology | Epithelial Cells - drug effects | Humans | Glutamine - metabolism | Electron Transport Complex I - metabolism | Glutamate Dehydrogenase - antagonists & inhibitors | Cell Death - drug effects | Kidney Tubules, Proximal - enzymology | Epithelial Cells - cytology | Glutamate Dehydrogenase - metabolism | Cell Line | Kidney Tubules, Proximal - cytology | Glucosides - pharmacology | Electron Transport Complex I - antagonists & inhibitors | Citric Acid Cycle - drug effects | Alanine - metabolism | Canagliflozin - adverse effects | Mitochondria - drug effects | Glucosides - metabolism | Metabolomics - methods | Epithelial Cells - enzymology | Benzhydryl Compounds - pharmacology | Glutamic Acid - metabolism | Hypoglycemic Agents - adverse effects | Benzhydryl Compounds - metabolism | Kidney Tubules, Proximal - drug effects | Cell proliferation | Glutamate dehydrogenase | Tricarboxylic acid cycle | Metabolomics | Alanine | Renal function | Kidneys | Dehydrogenases | Epithelial cells | Diabetes mellitus | Cytotoxicity | Amino acids | Glucose transport | Patients | Electron transport chain | Side effects | Mitochondria | Metabolites | Sodium | Cell death | Diabetes mellitus (non-insulin dependent) | Clear cell-type renal cell carcinoma | Glutamine
Journal Article
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
The aim of this work was to evaluate the efficacy and safety of canagliflozin vs placebo and sitagliptin in patients with type 2 diabetes who were being... 
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | GLIPIZIDE | ADD-ON | SULFONYLUREA | DAPAGLIFLOZIN | MELLITUS | INADEQUATE GLYCEMIC CONTROL | DIET | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | 52-WEEK | INHIBITOR | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
Journal Article
Diabetes Care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
Journal Article
American Journal of Emergency Medicine, ISSN 0735-6757, 2014, Volume 33, Issue 4, pp. 604.e3 - 604.e4
Highlights • Euglycemic DKA should be treated aggressively with IV fluids and insulin. • SGL-2 Inhibitors are contraindicated in Type I Diabetes. • Consider... 
Emergency | EMERGENCY MEDICINE | CANAGLIFLOZIN | Reports | Dextrose | Glucose | Hyperglycemia | Emergency medical care | Insulin
Journal Article
International Journal of Clinical Practice, ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
AimsCanagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind,... 
BODY-WEIGHT | MEDICINE, GENERAL & INTERNAL | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | GLYCEMIC CONTROL | PLACEBO | ADD-ON | DAPAGLIFLOZIN | DOUBLE-BLIND | 2 SGLT2 INHIBITOR | IMPROVES INDEXES | BETA-CELL FUNCTION | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Endocrinology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 7, pp. 644 - 657
In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor... 
MEDICINE, GENERAL & INTERNAL | METAANALYSIS | ATRIAL-NATRIURETIC-PEPTIDE | RATIONALE | INTENSIVE GLUCOSE CONTROL | PLACEBO-CONTROLLED TRIAL | OUTCOMES | INHIBITORS | STAGE KIDNEY-DISEASE | PROGRESSION | BASE-LINE CHARACTERISTICS | Hypoglycemic Agents - therapeutic use | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Kidney Diseases - mortality | Male | Canagliflozin - adverse effects | Disease Progression | Foot - surgery | Glomerular Filtration Rate - drug effects | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Amputation - statistics & numerical data | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Heart | Complications and side effects | Care and treatment | Abnormalities | Amputation | Myocardial infarction | Heart attacks | Body weight | Clinical trials | Cardiovascular disease | Blood pressure | Drug dosages | Heart failure | Cerebral infarction | Stroke | Statistical analysis | Kidneys | Metatarsal | Diabetes mellitus | Toe | FDA approval | Glomerular filtration rate | Medicine | Studies | Side effects | Sodium | Diabetes | Kidney diseases | Cardiovascular diseases | Health risk assessment | Kidney transplantation
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2014, Volume 16, Issue 5, pp. 467 - 477
Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM)... 
thiazolidinediones | metformin | type 2 diabetes | phase 3 study | inhibitor | SGLT2 | Type 2 diabetes | Metformin | Phase 3 study | SGLT2 inhibitor | Thiazolidinediones | GLYCEMIC CONTROL | PLACEBO | ADD-ON | SULFONYLUREA | MONOTHERAPY | SITAGLIPTIN | BODY-WEIGHT | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITOR | PANCREATIC-FUNCTION | Thiophenes - therapeutic use | Triazoles - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Pyrazines - administration & dosage | Lipids | Male | Thiophenes - administration & dosage | Genital Diseases, Female - chemically induced | Thiazolidinediones - administration & dosage | Hypoglycemic Agents - administration & dosage | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Candidiasis - chemically induced | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Diuretics, Osmotic - adverse effects | Double-Blind Method | Genital Diseases, Male - chemically induced | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucose metabolism | Care and treatment | Analysis | Low density lipoproteins | Hemoglobin | Glucose | Dextrose | Drug therapy | Diabetes | Original
Journal Article